WG
RVNC

Winton Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Winton Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,150
Closed -$274K – 1061
2022
Q3 		$274K Buy
+10,150
New +$206K 0.02% 821
2020
Q3 		– Sell
-10,460
Closed -$255K – 1635
2020
Q2 		$255K Buy
+10,460
New +$206K 0.01% 1316

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Winton Group's RVNC Position: Q4 2022 in Review

Winton Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 10,150 shares — an estimated $274K sold.

Winton Group first reported a position in RVNC in Q2 2020 and held it in 2 quarters. The position peaked at $274K in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • Winton Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Winton Group sold 10,150 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $274K.
  • Winton Group first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • Winton Group's Revance Therapeutics, Inc. position peaked at $274K in Q3 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Winton Group's 13F filing for Q4 2022, filed 14 Feb 2023.